{"id":"NCT01002742","sponsor":"Medical College of Wisconsin","briefTitle":"Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)","officialTitle":"A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2012-01","completion":"2013-06","firstPosted":"2009-10-27","resultsPosted":"2016-05-27","lastUpdate":"2023-01-04"},"enrollment":236,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Graft-versus-Host Disease","Immune System Disorders"],"interventions":[{"type":"DRUG","name":"Mycophenolate Mofetil","otherNames":["CellceptÂ®","MMF"]},{"type":"DRUG","name":"Placebo","otherNames":["Inactive drug"]}],"arms":[{"label":"Placebo","type":"EXPERIMENTAL"},{"label":"Mycophenolate Mofetil","type":"EXPERIMENTAL"}],"summary":"The study is a Phase III, randomized double blind, placebo controlled, and trial evaluating the addition of Mycophenolate mofetil (MMF) vs. placebo to systemic corticosteroids as initial therapy for acute Graft Vs Host Disease (GVHD). The primary endpoint will be GVHD free survival at Day 56 post randomization.","primaryOutcome":{"measure":"GVHD-free Survival","timeFrame":"Day 56","effectByArm":[{"arm":"Placebo","deltaMin":60,"sd":null},{"arm":"Mycophenolate Mofetil","deltaMin":69,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":13},"locations":{"siteCount":36,"countries":["United States"]},"refs":{"pmids":["25170121","32081787"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":119},"commonTop":[]}}